Company Overview of Wacker Biosolutions
Wacker Biosolutions offers tailored and innovative solutions and products based on advanced biotech processes for the food, pharmaceutical, and agrochemical industries. The company is headquartered in Munich, Germany. Wacker Biosolutions operates as a subsidiary of Wacker Chemie AG.
49 89 6279-1484
49 89 6279-2921
Key Executives for Wacker Biosolutions
Wacker Biosolutions does not have any Key Executives recorded.
Wacker Biosolutions Key Developments
Wacker Biosolutions Announces Earnings Results for the First Quarter Ended March 31, 2017
Apr 27 17
Wacker Biosolutions announced earnings results for the first quarter ended March 31, 2017. For the quarter, the company generated total sales of EUR 51.4 million from January through March 2017, up by around 4% from a year earlier of EUR 49.6 million. Higher volumes and positive exchange-rate effects were the key drivers of this growth. The company exceeded it’s the fourth quarter of 2016 sales figure of EUR 49.6 million by 4% as well. EBITDA at the company reached EUR 10.6 million in the reporting quarter, a good 10% higher than a year ago of EUR 9.6 million. The key factors behind this growth were higher sales and the division's good cost situation, which was also due to high plant-utilization levels. The company exceeded its prior-quarter figure of EUR 7.1 million by 49%.
Wacker Biosolutions Announces Earnings Results for the Year 2016; Provides Earnings Guidance for the Year 2017
Mar 14 17
Wacker Biosolutions announced earnings results for the year 2016. For the year, the company reported sales trend was positive too. Sales rose by around 5% in 2016 to EUR 206.4 million compared to EUR 197.1 million a year ago. It was essentially higher volumes that spurred the increase, while lower prices had the opposite effect. EBITDA increased by 15% to EUR 37.0 million compared to EUR 32.2 million a year ago, mainly due to volume growth and high plant utilization.
For the year 2017, sales forecast is for a low-single-digit percentage increase, chiefly driven by products for the pharmaceutical and agrochemical industries. Integration costs for the new site in Spain will impact 2017's EBITDA, which will be significantly lower than last year.
WACKER BIOSOLUTIONS Reports Earnings Results for the Second Quarter Ended June 30, 2015; Provides Earnings Guidance for the Full Year of 2015
Aug 3 15
WACKER BIOSOLUTIONS reported earnings results for the second quarter ended June 30, 2015. For the quarter, the company generated total sales of EUR 52.7 million against EUR 46.6 million a year ago, 13% more than a year ago. Favorable exchange rates and higher prices were the main drivers of this growth. The company also further enhanced its EBITDA which at EUR 9.5 million was up by about 16% over second quarter of 2014 of EUR 8.2 million. Higher sales were the main factor driving this growth.
The company expects to post substantial growth in 2015. Now that Scil Proteins Production GmbH in Halle (Germany) has been integrated, the division sees further growth potential for its biologics business. EBITDA should also show a clear year-over-year increase.
Similar Private Companies By Industry
Recent Private Companies Transactions
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries